Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

The postpartum depression market growth is expected to accelerate over the coming years, driven by increasing awareness, improved screening practices, and rising diagnosis rates among new mothers. The market is also benefiting from the introduction of novel therapies, including Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others, and innovative drug delivery approaches that address unmet clinical needs.

LAS VEGAS, Aug. 25, 2026 /PRNewswire/ -- Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Postpartum Depression Market Summary

• The total postpartum depression treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounted for the largest postpartum depression treatment market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• In 2025, the total diagnosed prevalent cases of maternal PPD in the 7MM were ~1.3 million, and this number is expected to rise during the forecast period.
• Leading postpartum depression companies, such as Reunion Neuroscience, TWi Biotechnology, Lipocine, GH Research, and others, are developing new postpartum depression treatment drugs that can be available in the postpartum depression market in the coming years. 
• The promising postpartum depression therapies in clinical trials include Luvesilocin (RE104), NORA520, LPCN 1154, GH001, and others.

Discover more about the global postpartum depression drugs industry @ https://www.delveinsight.com/report-store/postpartum-depression-ppd-market

Key Factors Driving the Growth of the Postpartum Depression Market 

• Increasing Prevalence of Postpartum Depression: Rising awareness and improved diagnosis have highlighted the significant global burden of PPD, with millions of women affected annually. The growing patient population is creating sustained demand for effective pharmacological and non-pharmacological treatment options.
• Expansion of Maternal Mental Health Screening Programs: Implementation of routine depression screening during pregnancy and the postpartum period is facilitating earlier identification and intervention, supporting treatment uptake.
• Demand for Rapid Symptom Relief: Unlike traditional antidepressants that may require several weeks to achieve clinical benefit, newer neuroactive steroid therapies offer faster onset of action, addressing a critical unmet need in postpartum care.
• Robust Clinical Pipeline and Ongoing Research: Pharmaceutical companies are actively investing in the development of next-generation therapies such as Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others. Positive clinical trial outcomes and regulatory advancements are expected to strengthen market growth over the forecast period.

Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that among emerging therapies, luvesilocin represents one of the most differentiated pipeline assets due to its novel serotonergic neuroplastogen mechanism and potential to deliver rapid and durable antidepressant effects following a single administration. Meanwhile, LPCN 1154 and NORA520 are expanding the neuroactive steroid class, with both candidates aiming to optimize GABA-A receptor modulation and provide rapid symptom improvement.

Postpartum Depression Market Analysis

• Psychosocial and psychological interventions remain the first-line treatment for patients with mild-to-moderate postpartum depression (PPD). 
• Among pharmacological options, selective serotonin reuptake inhibitors (SSRIs) are generally considered the preferred first-line antidepressants, particularly for patients who have previously responded well to these agents and for those requiring medications with a favorable safety profile during breastfeeding. 
• For individuals with moderate-to-severe PPD, a combination of antidepressant therapy and psychotherapy is typically recommended to achieve optimal clinical outcomes.
• The approved treatment landscape for PPD remains limited, with zuranolone, developed by Sage Therapeutics and Biogen, currently serving as the only approved therapy. 
• By positively modulating GABA-A receptors, zuranolone offers a targeted mechanism of action distinct from conventional antidepressants.
• In April 2025, the U.S. FDA withdrew the approval of brexanolone (ZULRESSO) for PPD following a request from Sage Therapeutics. The company cited commercial considerations and its strategic decision to focus resources on the commercialization of zuranolone.
• The emerging PPD pipeline is being advanced by several companies, including Reunion Neuroscience with Luvesilocin (RE104), Lipocine with LPCN 1154, and Neurocrine Biosciences with NORA520. 
• These investigational therapies are designed to provide faster symptom improvement, longer-lasting therapeutic benefits, and greater convenience for patients compared with traditional antidepressant treatments.
• Beyond approved and investigational drugs, PPD management also encompasses psychosocial, psychological, pharmacological, and somatic interventions. 
• However, existing treatment options may not adequately address the full spectrum or severity of PPD, underscoring the substantial unmet need and creating significant opportunities for the development of innovative therapeutic approaches.

Postpartum Depression Competitive Landscape

Some of the postpartum depression drugs under development include Luvesilocin (RE104) (Reunion Neuroscience), NORA520 (TWi Biotechnology), LPCN 1154 (Lipocine), GH001 (GH Research), and others.

Reunion Neuroscience's Luvesilocin is a proprietary, patented prodrug of 4-OH-DiPT being developed as a potential best-in-class therapy and is administered through a subcutaneous (SC) injection. The company plans to begin a pivotal Phase III clinical trial for postpartum depression (PPD) in 2026, with positive outcomes potentially supporting its regulatory approval. Luvesilocin has received Breakthrough Therapy Designation (BTD) from the US FDA for the treatment of PPD. In the Phase II RECONNECT trial involving adult women with moderate-to-severe PPD, the candidate produced substantial improvements in depressive symptoms while demonstrating a generally favorable safety and tolerability profile.

Lipocine's LPCN 1154 is an oral formulation of brexanolone, a non-SSRI therapy that is chemically identical to the naturally occurring neurosteroid allopregnanolone. The candidate is being developed as a potential rescue treatment for PPD, offering rapid symptom relief within hours without requiring intensive patient monitoring. LPCN 1154 has shown clinically meaningful tolerability with minimal central nervous system (CNS) depressant effects and avoids the dissociative or hallucinogenic risks associated with psychedelic-based therapies, making it a promising option for safe at-home treatment while supporting the maternal–infant bond. Lipocine has submitted applications to the FDA for Breakthrough Therapy and Fast Track designations and has also filed the Phase III validation study protocol as part of its planned regulatory pathway.

The anticipated launch of these emerging therapies are poised to transform the postpartum depression market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the postpartum depression market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

Discover more about the postpartum depression drugs in development @ Postpartum Depression Clinical Development

Recent Developments in the Postpartum Depression Market

• In May 2026, Lipocine announced that its Phase III clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting.
• In May 2026,  Reunion Neuroscience presented the full results of RECONNECT, a Phase II trial evaluating luvesilocin in adult female patients with moderate-to-severe PPD, in an oral presentation at the ASCP Annual Meeting 2026.
• In April 2026, Lipocine announced topline results from its Phase III trial evaluating LPCN 1154 for the treatment of PPD. 
• In February 2026, Reunion Neuroscience, Inc. announced that the FDA has awarded Breakthrough Therapy Designation (BTD) to luvesilocin (formerly known as RE104) for the treatment of postpartum depression (PPD).
• In November 2025, TWi Biotechnology reported results from a Phase II clinical trial of NORA520 for PPD, reporting that the combined treatment groups did not achieve a statistically significant difference compared with placebo, highlighting limited efficacy in this study.

Postpartum Depression Epidemiology Segmentation

The postpartum depression epidemiology section provides insights into the historical and current postpartum depression patient pool and forecasted trends for the leading markets. Among the 7MM, the US accounted for the largest share of diagnosed prevalent cases of maternal PPD in 2025, with ~700,000 cases. The postpartum depression treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

• Maternal PPD Total Diagnosed Prevalent Cases

Scope of the Postpartum Depression Market Report

• Postpartum Depression Patient Population Forecast
• Postpartum Depression Therapeutics Market Size
• Postpartum Depression Pipeline Analysis
• Postpartum Depression Market Size and Trends
• Postpartum Depression Market Opportunity
• Postpartum Depression Market Unmet Needs
• KOL's Views on Postpartum Depression
• Postpartum Depression Market Access and Reimbursement

Download the report to understand the postpartum depression drug market @ Postpartum Depression Treatment Market

Table of Contents

Related Reports

Postpartum Depression Clinical Trial Analysis

Postpartum Depression Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PPD companies, including GH Research, Reunion Neuroscience, Lipocine, Brii Biosciences Limited, and others.

Maternal Mental Health Market

Maternal Mental Health Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key maternal mental health companies, including Biogen Inc., Sage Therapeutics, Inc., Therapy Mama., Canopie., Postpartum Support International, SonderMind Inc., Maven Clinic Co., Wildflower Health, Hims & Hers Health, Inc., Medela, Bausch Health Companies Inc., Maternal Mental Health Alliance, MumsAid, Cedars-Sinai, Marinus Pharmaceuticals, Brii Biosciences Limited, and others.

Bipolar Depression Market

Bipolar Depression Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bipolar depression companies, including Xenon Pharmaceuticals, Autobahn Therapeutics, AbbVie, Alto Neuroscience, NRx Pharmaceuticals, LB Pharmaceuticals, and others.

Treatment-resistant Depression Market

Treatment-resistant Depression Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key TRD companies including Navitor Pharmaceuticals, Supernus Pharmaceuti, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com 

SOURCE DelveInsight Business Research, LLP